Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 8
2004 4
2005 7
2006 17
2007 14
2008 23
2009 23
2010 30
2011 24
2012 33
2013 55
2014 52
2015 60
2016 57
2017 62
2018 76
2019 79
2020 95
2021 91
2022 88
2023 79
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

920 results

Results by year

Filters applied: . Clear all
Page 1
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.
Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil EM, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón A, Murillo L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero JA, Bianco R, Formisano L, Turner N, Martín M. Guerrero-Zotano Á, et al. Clin Cancer Res. 2023 Apr 14;29(8):1557-1568. doi: 10.1158/1078-0432.CCR-22-2206. Clin Cancer Res. 2023. PMID: 36749874 Free PMC article. Clinical Trial.
PURPOSE: In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and to discover therapeutic targets to reverse this resistance. Non-luminal breast …
PURPOSE: In hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC), it is imperative to identify patients who respond p …
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models.
Xu H, George E, Kinose Y, Kim H, Shah JB, Peake JD, Ferman B, Medvedev S, Murtha T, Barger CJ, Devins KM, D'Andrea K, Wubbenhorst B, Schwartz LE, Hwang WT, Mills GB, Nathanson KL, Karpf AR, Drapkin R, Brown EJ, Simpkins F. Xu H, et al. Cell Rep Med. 2021 Sep 23;2(9):100394. doi: 10.1016/j.xcrm.2021.100394. eCollection 2021 Sep 21. Cell Rep Med. 2021. PMID: 34622231 Free PMC article.
CCNE1-amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated with platinum resistance and poor survival, representing a clinically unmet need. ...Low-dose WEE1i-ATRi synergistically decreases viability and colony formation and increa …
CCNE1-amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated with platinum resistance and poo …
Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT Jr, Drapkin R. Kroeger PT Jr, et al. Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34. doi: 10.1097/GCO.0000000000000340. Curr Opin Obstet Gynecol. 2017. PMID: 27898521 Free PMC article. Review.
SUMMARY: The fallopian tube secretory cell is the cell of origin for the majority of ovarian cancers. Although it remains unclear what triggers neoplastic transformation of these cells, certain tumors exhibit loss of BRCA function or amplification of CCNE1. These al …
SUMMARY: The fallopian tube secretory cell is the cell of origin for the majority of ovarian cancers. Although it remains unclear wha …
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. Gallo D, et al. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. Nature. 2022. PMID: 35444283 Free PMC article.
Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian cancer, uterine tumours and gastro-oesophageal cancers, where high cyclin E levels are associated with genome instability, wh …
Amplification of the CCNE1 locus on chromosome 19q12 is prevalent in multiple tumour types, particularly in high-grade serous ovarian …
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Yao S, et al. Sci Rep. 2022 May 24;12(1):8701. doi: 10.1038/s41598-022-12669-5. Sci Rep. 2022. PMID: 35610322 Free PMC article. Review.
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We revi …
Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with …
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30. Gynecol Oncol. 2021. PMID: 33934848 Free PMC article. Review.
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. ...Unfortunately, despite these efforts, survival outcomes still rema …
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but …
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities.
Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. Knudsen ES, et al. Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448. Cell Rep. 2022. PMID: 35235778 Free PMC article.
Here, we find that the requirement for different CDK activities and cyclins in driving cancer cell cycles is highly heterogeneous. The differential gene requirements associate with tumor origin and genetic alterations. ...Mining therapeutic sensitivities shows that there a …
Here, we find that the requirement for different CDK activities and cyclins in driving cancer cell cycles is highly heterogeneous. Th …
USP15 negatively regulates lung cancer progression through the TRAF6-BECN1 signaling axis for autophagy induction.
Kim MJ, Min Y, Jeong SK, Son J, Kim JY, Lee JS, Kim DH, Lee JS, Chun E, Lee KY. Kim MJ, et al. Cell Death Dis. 2022 Apr 14;13(4):348. doi: 10.1038/s41419-022-04808-7. Cell Death Dis. 2022. PMID: 35422093 Free PMC article.
Herein, we provide novel molecular and cellular mechanisms involved in the negative effect of ubiquitin-specific peptidase 15 (USP15) on lung cancer progression. Clinical data of the TCGA and primary non-small cell lung cancer (NSCLC) patients (n = 41) revealed that …
Herein, we provide novel molecular and cellular mechanisms involved in the negative effect of ubiquitin-specific peptidase 15 (USP15) on lun …
Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication.
Zeng J, Hills SA, Ozono E, Diffley JFX. Zeng J, et al. Cell. 2023 Feb 2;186(3):528-542.e14. doi: 10.1016/j.cell.2022.12.036. Epub 2023 Jan 20. Cell. 2023. PMID: 36681079 Free article.
Whole-genome duplication (WGD) is a frequent event in cancer evolution and an important driver of aneuploidy. The role of the p53 tumor suppressor in WGD has been enigmatic: p53 can block the proliferation of tetraploid cells, acting as a barrier to WGD, but can also promo …
Whole-genome duplication (WGD) is a frequent event in cancer evolution and an important driver of aneuploidy. The role of the p53 tum …
CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
Zheng X, Chen L, Liu W, Zhao S, Yan Y, Zhao J, Tian W, Wang Y. Zheng X, et al. Hereditas. 2023 Mar 24;160(1):13. doi: 10.1186/s41065-023-00273-0. Hereditas. 2023. PMID: 36964635 Free PMC article.
BACKGROUND: CCNE1 plays an important oncogenic role in several tumors, especially high-stage serous ovarian cancer and endometrial cancer. Nevertheless, the fundamental function of CCNE1 has not been explored in multiple cancers. Therefore, bioi …
BACKGROUND: CCNE1 plays an important oncogenic role in several tumors, especially high-stage serous ovarian cancer and endomet …
920 results